Cytogenetic findings in adult secondary acute myeloid leukemia (AML): Frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML

Cancer Genetics and Cytogenetics

Volumn 202, Issue 2, 2010, Pages 108-122

  Preiss, Birgitte S ^a   Bergman, Olav J ^a,b   Friis, Lone S ^a   Sørensen, Anne G ^a,c   Frederiksen, Michael ^d   Gadeberg, Ole V ^c   Mourits Andersen, Torben ^b   Oestergaard, Birthe ^c   Kerndrup, Gitte B ^a,c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d Section of Cardiology   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CLONE; CENTROMERE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CORRELATION ANALYSIS; CYTOGENETICS; DENMARK; FEMALE; GENDER; HEMATOLOGIC DISEASE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MARKER CHROMOSOME; METASTASIS; MITOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; ADOLESCENT; AGE DISTRIBUTION; GENETICS; HUMAN CHROMOSOME; INCIDENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PLOIDY; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN; CYTOGENETIC ANALYSIS; DENMARK; HUMANS; INCIDENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PLOIDIES; YOUNG ADULT;

EID: 77957023526     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.06.013     Document Type: Article

References (34)

1. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica 1999, 84:937-945.
2. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
3. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
4. Mauritzson N., Albin M., Rylander L., Billstrom R., Ahlgren T., Mikoczy Z., et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002, 16:2366-2378.
5. Preiss B.S., Kerndrup G.B., Schmidt K.G., Sorensen A.G., Clausen N.A., Gadeberg O.V., et al. Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. Br J Haematol 2003, 123:219-234.
6. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
7. WHO classification of tumours. Pathology of haematopoietic and lymphoid tissues 2001, IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
8. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:460-462.
9. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991, 78:325-329.
10. Pedersen R.K., Kerndrup G.B., Sorensen A.G., Mourits-Andersen T., Gram-Hansen P., Pulczynski S., et al. Cytogenetic aberrations in adult acute lymphocytic leukemia: optimal technique may influence the results. Cancer Genet Cytogenet 2001, 128:7-10.
11. Yunis J.J. High resolution of human chromosomes. Science 1976, 191:1268-1270.
12. ISCN: an international system for human cytogenetic nomenclature 2009, S. Karger, Basel. L.G. Schaffer, M.L. Slovak, L.J. Campbell (Eds.).
13. Mitelman database of chromosome aberrations in cancer Available at:, Last Accessed April 3, 2010. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
14. Astrom M., Bodin L., Nilsson I., Tidefelt U. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 2000, 82:1387-1392.
15. Hann I.M., Stevens R.F., Goldstone A.H., Rees J.K., Wheatley K., Gray R.G., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997, 89:2311-2318.
16. Godwin J.E., Kopecky K.J., Head D.R., Willman C.L., Leith C.P., Hynes H.E., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998, 91:3607-3615.
17. Lowenberg B., Suciu S., Archimbaud E., Ossenkoppele G., Verhoef G.E., Vellenga E., et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997, 90:2952-2961.
18. Lowenberg B., Suciu S., Archimbaud E., Haak H., Stryckmans P., de Cataldo R., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998, 16:872-881.
19. Damiani D., Michieli M., Ermacora A., Candoni A., Raspadori D., Geromin A., et al. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 1998, 83:290-297.
20. Jackson G.H., Taylor P.R., Iqbal A., Galloway M.J., Turner G., Haynes A., et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 1997, 11:1193-1196.
21. Ruutu T., Almqvist A., Hallman H., Honkanen T., Jarvenpaa E., Jarventie G., et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia 1994, 8:11-15.
22. Pagana L., Pulsoni A., Tosti M.E., Avvisati G., Mele L., Mele M., et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001, 112:109-117.
23. Block A.W., Carroll A.J., Hagemeijer A., Michaux L., van L.K., Olney H.J., et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:401-412.
24. Fonatsch C., Gudat H., Lengfelder E., Wandt H., Silling-Engelhardt G., Ludwig W.D., et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994, 8:1318-1326.
25. Arthur D.C., Berger R., Golomb H.M., Swansbury G.J., Reeves B.R., Alimena G., et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989, 40:203-216.
26. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D., et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996, 88:4296-4303.
27. Horiike S., Misawa S., Kaneko H., Sasai Y., Kobayashi M., Fujii H., et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos. 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 1999, 13:1235-1242.
28. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
29. Iurlo A., Mecucci C., Van O.A., Michaux J.L., Boogaerts M., Noens L., et al. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 1989, 43:227-241.
30. Le Beau M.M., Albain K.S., Larson R.A., Vardiman J.W., Davis E.M., Blough R.R., et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986, 4:325-345.
31. Johansson B., Mertens F., Heim S., Kristoffersson U., Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 1991, 47:17-27.
32. Andersen M.K., Larson R.A., Mauritzson N., Schnittger S., Jhanwar S.C., Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:395-400.
33. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002, 99:1909-1912.
34. Andersen M.K., Christiansen D.H., Pedersen-Bjergaard J. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. Genes Chromosomes Cancer 2005, 42:358-371.